AtheroGenics Inc., of Atlanta, promoted David Edwards to senior director of toxicology and early development, Bruce Johnson to senior director of developmental chemistry, and Felicia Ford-Rice to director of quality assurance and compliance.
Corvas International Inc., of San Diego, appointed Stephen Keane vice president, corporate development.
Deltagen Inc., of Menlo Park, Calif., appointed Paul Laland vice president of corporate communications.
ImmunoGen Inc., of Cambridge, Mass., appointed Gregg Beloff vice president and chief financial officer.
Iomed Inc., of Salt Lake City, appointed Stephen Warren vice president of clinical and scientific affairs, ophthalmics.
Isis Pharmaceuticals Inc., of Carlsbad, Calif., elected Frederick Muto to its board.
Molecular Mining Corp., of Kingston, Ontario, appointed Larry Greller director of mathematical biology and systems modeling.
Paradigm Genetics Inc., of Research Triangle Park, N.C., named Mark Skaletsky to its board.
Stressgen Biotechnologies Corp., of Victoria, British Columbia, added Donald Tartre as vice president and chief financial officer.
Structural GenomiX Inc., of San Diego, hired Sheryl Silverstein as senior director of intellectual property.
Synsorb Biotech Inc., of Calgary, Alberta, appointed Bill Hogg vice president, finance and chief financial officer.
Transkaryotic Therapies Inc., of Cambridge, Mass., appointed Anthony Murabito vice president, management information systems, and promoted Daniel Geffken to senior vice president, finance and chief financial officer.